Financial Daily from THE HINDU group of publications
Sunday, Sep 25, 2005

Port Info

Group Sites

Home Page - Regulatory Bodies & Rulings
Industry & Economy - Alternative Medicines
Government - Policy

Govt to set new standards for ayurvedic, unani drugs

Nithya Subramanian

New Delhi , Sept. 24

FOLLOWING the warnings issued by health regulators in the UK and Canada, the Health Ministry is putting in place basic parameters for companies manufacturing ayurvedic and unani products.

It is planning to set heavy metal limits for these products. The presence of heavy metals in certain ayurvedic products had led Health Canada and Medicines and Healthcare products Regulatory Agency (MHRA) of the UK to advise consumers not to use them. They had said that many of the products might contain mercury and arsenic, and cause severe nausea, vomiting, and abdominal pain.

Health Ministry officials said, "The main concern of the foreign regulators is the harmful effects of heavy metals. We felt that this needs to be checked."

Some of the products that had come under the scanner were Zandu Pharmaceuticals' Maha Sudharshan Churna Powder, Yograj Guggul tablets and Sudarshan tablets; Dabur India's Maha Sudharshan Churna and Shilajit capsules; Karela Capsules manufactured by Himalaya Drug Company; and Safi Liquid from Hamdard Wakf-India.

Besides this, the Health Ministry is also focusing on improving the manufacturing standards for ayurvedic products. "The manufacturing facilities would have to be GMP- (Good Manufacturing Practices) compliant, though this has been notified in the Drugs and Cosmetics Act.

Action would be taken against those companies, which do not have the systems in place," the officials said.

Also, the Government is planning to make labelling of the ingredients mandatory. "Companies will have to list out all the inputs, including the metals present," they added. The Government has also initiated a Golden Triangle Project in partnership with the Indian Council of Medical Research and the Council of Scientific and Industrial Research (CSIR) for the scientific validation of existing ayurvedic, siddha and unani drugs, and the development of new drugs.

The Union Health Minister, Dr Anbumani Ramadoss, said that the Government would spend Rs 120 crore on the project. According to the Ayurvedic Drug Manufacturers' Association, the globalisation of the Indian system of medicine and health would easily generate Rs 10,000 crore every year.

While the current market for ayurvedic drugs is worth Rs 5,000 crore, more than 90 per cent of this industry comprises over 6,500 small-scale players. The Health Minister said that a traditional knowledge digital library would be set up for listing formulations available in the ancient scriptures and other sources.

When spoken to earlier, companies Dabur and Himalaya had said that they had conducted independent research that proved the safety of their products.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Tata Safari Dicor

Stories in this Section
Sabarimala Temple all set for Rs 1,000-cr facelift — IL&FS to raise funds from market

Mukta Arts: CLB gives nod for further probe
Govt to set new standards for ayurvedic, unani drugs
TRAI proposals on rural tele-density to be sent to DoT soon
Soon, your vegetable hawker may be graded
Domestic investors pull out Rs 16,000 cr — Net sales on NSE since June

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line